Sign in Subscribe
COVID-19

Changing COVID-19 Vaccine Recommendations in the US: A New Era of Evidence-Based Approaches

Strategic Insights

— 2 min read

As of Tuesday, the US Centers for Disease Control and Prevention (CDC) has removed COVID-19 vaccines from its list of recommended immunizations for pregnant women and "healthy" children. This move comes after a joint announcement by the US Department of Health and Human Services (HHS) secretary Robert F. Kennedy Jr. and National Institutes of Health (NIH) director Jay Bhattacharya, M.D., Ph.D. The change in recommendation is attributed to a lack of clinical data supporting the need for repeat booster shots in children. The FDA is now demanding "robust, gold-standard data" to approve new vaccines, including placebo-controlled clinical trials with six months of follow-up and immunologic endpoints, according to FDA commissioner Marty Makary, M.D., Ph.D.

Key Takeaways:

  • The CDC has removed COVID-19 vaccines from its list of recommended immunizations for pregnant women and "healthy" children due to a lack of clinical data supporting repeat booster shots in children.
  • The FDA will now require "robust, gold-standard data" to approve new vaccines, including placebo-controlled clinical trials with six months of follow-up and immunologic endpoints.
  • The FDA's shift in policy is reflected in the recent approval of Novavax's vaccine, which limits its use to individuals 65 years and older or those with at least one underlying health condition that puts them at high risk for severe COVID outcomes.
  • The FDA's Vaccine and Related Biological Products Advisory Committee (VRBPAC) has unanimously voted in favor of reformulated vaccines designed to better match the current evolution of the COVID virus.
  • Moderna and Pfizer are expected to update their COVID vaccine formulas, but the regulatory standards for these updates are still unclear.
  • The CDC's Advisory Committee on Immunization Practices will meet next month to discuss vaccine recommendations.
  • The shift in policy remains a subject of discussion among experts, with some concerned that new testing requirements could delay the delivery of updated vaccines.

Statistics:

  • The COVID-19 vaccines will no longer be recommended for pregnant women and "healthy" children.
  • The FDA will now require "robust, gold-standard data" to approve new vaccines.
  • The FDA's new policy reflects a shift towards evidence-based approaches, with a focus on placebo-controlled clinical trials with six months of follow-up and immunologic endpoints.
  • The FDA has already approved Novavax's vaccine, which has usage limitations.
  • The FDA's Vaccine and Related Biological Products Advisory Committee (VRBPAC) has unanimously voted in favor of reformulated vaccines.
  • Moderna and Pfizer are expected to update their COVID vaccine formulas.

Sources:

  • (Robert F. Kennedy Jr.'s X account post)
  • (Jay Bhattacharya, M.D., Ph.D.'s statement)
  • (Marty Makary, M.D., Ph.D.'s article in The New England Journal of Medicine)
  • (FDA policy)
  • (Stat News)

Read more